Cargando…

Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges

Cancer is one of the main causes of death worldwide. To date, and despite the advances in conventional treatment options, therapy in cancer is still far from optimal due to the non-specific systemic biodistribution of antitumor agents. The inadequate drug concentrations at the tumor site led to an i...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez, Francisco, Caruana, Pablo, De la Fuente, Noa, Español, Pía, Gámez, María, Balart, Josep, Llurba, Elisa, Rovira, Ramón, Ruiz, Raúl, Martín-Lorente, Cristina, Corchero, José Luis, Céspedes, María Virtudes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221343/
https://www.ncbi.nlm.nih.gov/pubmed/35740909
http://dx.doi.org/10.3390/biom12060784
_version_ 1784732597992030208
author Rodríguez, Francisco
Caruana, Pablo
De la Fuente, Noa
Español, Pía
Gámez, María
Balart, Josep
Llurba, Elisa
Rovira, Ramón
Ruiz, Raúl
Martín-Lorente, Cristina
Corchero, José Luis
Céspedes, María Virtudes
author_facet Rodríguez, Francisco
Caruana, Pablo
De la Fuente, Noa
Español, Pía
Gámez, María
Balart, Josep
Llurba, Elisa
Rovira, Ramón
Ruiz, Raúl
Martín-Lorente, Cristina
Corchero, José Luis
Céspedes, María Virtudes
author_sort Rodríguez, Francisco
collection PubMed
description Cancer is one of the main causes of death worldwide. To date, and despite the advances in conventional treatment options, therapy in cancer is still far from optimal due to the non-specific systemic biodistribution of antitumor agents. The inadequate drug concentrations at the tumor site led to an increased incidence of multiple drug resistance and the appearance of many severe undesirable side effects. Nanotechnology, through the development of nanoscale-based pharmaceuticals, has emerged to provide new and innovative drugs to overcome these limitations. In this review, we provide an overview of the approved nanomedicine for cancer treatment and the rationale behind their designs and applications. We also highlight the new approaches that are currently under investigation and the perspectives and challenges for nanopharmaceuticals, focusing on the tumor microenvironment and tumor disseminate cells as the most attractive and effective strategies for cancer treatments.
format Online
Article
Text
id pubmed-9221343
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92213432022-06-24 Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges Rodríguez, Francisco Caruana, Pablo De la Fuente, Noa Español, Pía Gámez, María Balart, Josep Llurba, Elisa Rovira, Ramón Ruiz, Raúl Martín-Lorente, Cristina Corchero, José Luis Céspedes, María Virtudes Biomolecules Review Cancer is one of the main causes of death worldwide. To date, and despite the advances in conventional treatment options, therapy in cancer is still far from optimal due to the non-specific systemic biodistribution of antitumor agents. The inadequate drug concentrations at the tumor site led to an increased incidence of multiple drug resistance and the appearance of many severe undesirable side effects. Nanotechnology, through the development of nanoscale-based pharmaceuticals, has emerged to provide new and innovative drugs to overcome these limitations. In this review, we provide an overview of the approved nanomedicine for cancer treatment and the rationale behind their designs and applications. We also highlight the new approaches that are currently under investigation and the perspectives and challenges for nanopharmaceuticals, focusing on the tumor microenvironment and tumor disseminate cells as the most attractive and effective strategies for cancer treatments. MDPI 2022-06-04 /pmc/articles/PMC9221343/ /pubmed/35740909 http://dx.doi.org/10.3390/biom12060784 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Rodríguez, Francisco
Caruana, Pablo
De la Fuente, Noa
Español, Pía
Gámez, María
Balart, Josep
Llurba, Elisa
Rovira, Ramón
Ruiz, Raúl
Martín-Lorente, Cristina
Corchero, José Luis
Céspedes, María Virtudes
Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges
title Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges
title_full Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges
title_fullStr Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges
title_full_unstemmed Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges
title_short Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges
title_sort nano-based approved pharmaceuticals for cancer treatment: present and future challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221343/
https://www.ncbi.nlm.nih.gov/pubmed/35740909
http://dx.doi.org/10.3390/biom12060784
work_keys_str_mv AT rodriguezfrancisco nanobasedapprovedpharmaceuticalsforcancertreatmentpresentandfuturechallenges
AT caruanapablo nanobasedapprovedpharmaceuticalsforcancertreatmentpresentandfuturechallenges
AT delafuentenoa nanobasedapprovedpharmaceuticalsforcancertreatmentpresentandfuturechallenges
AT espanolpia nanobasedapprovedpharmaceuticalsforcancertreatmentpresentandfuturechallenges
AT gamezmaria nanobasedapprovedpharmaceuticalsforcancertreatmentpresentandfuturechallenges
AT balartjosep nanobasedapprovedpharmaceuticalsforcancertreatmentpresentandfuturechallenges
AT llurbaelisa nanobasedapprovedpharmaceuticalsforcancertreatmentpresentandfuturechallenges
AT roviraramon nanobasedapprovedpharmaceuticalsforcancertreatmentpresentandfuturechallenges
AT ruizraul nanobasedapprovedpharmaceuticalsforcancertreatmentpresentandfuturechallenges
AT martinlorentecristina nanobasedapprovedpharmaceuticalsforcancertreatmentpresentandfuturechallenges
AT corcherojoseluis nanobasedapprovedpharmaceuticalsforcancertreatmentpresentandfuturechallenges
AT cespedesmariavirtudes nanobasedapprovedpharmaceuticalsforcancertreatmentpresentandfuturechallenges